Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
Lyell Immunopharma
About
Lyell Immunopharma is an operator of a biotechnology company that develops cellular therapies to cure cancer.
- South San Francisco,California,United States
- https://lyell.com/
Details
- Last Funding Type
- Series A
- Industries
- Biotechnology,Health Care,Medical,Pharmaceutical
- Founded date
- Jan 1, 2018
- Operating Status
- Active
- Stock Symbol
- nasdaq:LYEL
- Legal Name
- Lyell Immunopharma, Inc.
Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses with adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 16, 2021 | IPO | $425M | — | — | — | Detail |
| Mar 12, 2020 | Series C | $492.99M | — | — | — | Detail |
| Oct 10, 2018 | Series A | — | 4 | — | — | Detail |
Investments
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Mar 31, 2021
Outpace Bio
|
Series A | $30M | Biotechnology | Yes |
|
Sep 30, 2020
Sonoma Pharmaceuticals
|
Post-IPO Equity | $70M | Health Care | — |
|
Sep 30, 2020
Sonoma BioTherapeutics
|
Series A | $30M | Biotechnology | — |
|
Mar 18, 2020
Cero Therapeutics
|
Series A | $40M | Biotechnology | — |
|
Mar 17, 2020
Eureka Therapeutics
|
Series E | $45M | Biotechnology | Yes |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
ARCH Venture Partners
|
— | Series A |
Arrive
|
— | Series A |
Bill & Melinda Gates Foundation
|
— | Series A |
|
|
— | Series A |
Employee Profiles
Exits
Lyell Immunopharma has had 1 exits. Lyell Immunopharma most notable exits include Sonoma Pharmaceuticals
| Date | Company Name | Exit Type | Industry | |
|---|---|---|---|---|
| Jan 25, 2007 | Sonoma Pharmaceuticals | IPO | Health Care | Detail |
